1. Home
  2. RCON vs SKYE Comparison

RCON vs SKYE Comparison

Compare RCON & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recon Technology Ltd.

RCON

Recon Technology Ltd.

HOLD

Current Price

$0.60

Market Cap

31.2M

Sector

Energy

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.82

Market Cap

27.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCON
SKYE
Founded
2007
2012
Country
China
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.2M
27.3M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
RCON
SKYE
Price
$0.60
$0.82
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
17.7K
182.1K
Earning Date
03-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,430,788.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.57
52 Week High
$7.16
$5.75

Technical Indicators

Market Signals
Indicator
RCON
SKYE
Relative Strength Index (RSI) 25.49 50.78
Support Level N/A $0.71
Resistance Level $1.04 $0.83
Average True Range (ATR) 0.09 0.08
MACD -0.02 -0.02
Stochastic Oscillator 11.06 48.46

Price Performance

Historical Comparison
RCON
SKYE

About RCON Recon Technology Ltd.

Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: